Newsletter · 2026-06-23 · Ashutosh Agarwal

SpaceX Prices the Largest IPO Ever as Issuance Surges and CME Sues the CFTC - Capital Markets: IPOs, M&A & Exchanges - Week of June 23, 2026

Capital-markets, IPO, M&A and exchanges newsletter for the week of June 23, 2026. The largest IPO in history priced and popped, the supply regime flipped from buybacks to heavy net issuance, CME sued the CFTC over prediction-market perps, and a new Warsh Fed turned hawkish on day one.

Capital Markets: IPOs, M&A & Exchanges

Week of June 23, 2026: SpaceX Prices the Largest IPO Ever as Issuance Surges and CME Sues the CFTC

A week for the deal-history books: the largest IPO ever priced and popped, the buyback era flipped on its head, an exchange sued its own regulator, and a new Fed chair tore up the playbook on day one.

The SpaceX print reopens the window, on its own terms. The week belonged to SpaceX, the biggest IPO in history, "bigger than Aramco," as Andy Constan put it on Excess Returns (June 16). The mechanics are the story. On The Wall Street Skinny (June 19), Kristen and Jen walked through how the deal "broke all the rules": instead of a roadshow and a built book, "Elon Musk just came down on high and said, we're going out at $135 price... a take it or leave it price. There was no matching supply and demand." The book came in roughly four times oversubscribed, ~$75 billion of stock against ~$250 billion of demand, with Fidelity alone reportedly bidding $5 billion. Priced at $135, the stock opened near $150 and traded into the $170s within 48 hours; The Rundown (June 22) later flagged shares above $200, against a Morningstar intrinsic-value estimate of just $63.

The float is what every PM should sit with. Constan's framing: SpaceX "sold $85 billion of stock... and they had $2 trillion of market cap. That means they issued 4% of the total company." On Prof G Markets (June 19), Barry Ritholtz likened the engineered scarcity to Rolex production constraints, a stock "marketed to retail, not institutions," with unlocks resolving over roughly twelve months into 2027. The Wall Street Skinny put it plainly: can it survive the other 95% unlocking?

The pipeline is the real signal. On Squawk Pod (June 16), SEC Chairman Paul Atkins said "the real story is other IPOs in the pipeline," pointing to mega-listings from Anthropic and OpenAI, both confirmed to have filed confidentially (Equity, June 17). Equity Mates (June 17) sized it: the two could raise ~$200 billion combined, dwarfing the ~$45 billion all US IPOs raised in 2025.

The supply regime is flipping, own this theme. Constan's core point on Excess Returns (June 16): we are leaving fifteen years of net share shrinkage (buybacks) and entering a year of heavy net issuance, he put 2026 net equity issuance at $600 to $700 billion. A cited JPMorgan projection (Trappin Tuesday's, June 19) has net issuance rising to $1.2 trillion by 2027, as Alphabet, Meta and Oracle line up secondaries alongside the SpaceX/OpenAI/Anthropic slate. "More shares for investors to invest in, less cash that investors hold," Constan explained, a slow-moving but real headwind for equities.

The debt side is moving even faster. On Morgan Stanley's Thoughts on the Market (June 18), Vishwas Patkar said AI-related debt issuance is "close to $250 billion" year-to-date and should double to "about $500 billion" for 2026, while high-yield data-center project finance has gone "from effectively $0 billion around the fall of last year to about $40 billion this year." His framing: a base case "similar to 1997, 1998, where credit was starting to finance the business cycle," with construction risk the dominant concern as first delivery dates hit in H2.

The M&A desk lit up. SpaceX paid ~$60 billion in all-stock for Cursor (Anyphere), a 50% premium and ~15x revenue, with a $10 billion breakup fee (This Week in Startups, June 18; Elon Musk Podcast, June 17). In media, Fox is acquiring Roku for ~$22 billion at $160/share, with Netflix reportedly outbid and now circling Lionsgate, though Fast Money (June 18) noted Netflix has denied the Lionsgate interest. In healthcare, AbbVie is buying Apogee Therapeutics for $10.9 billion, following GSK's ~$11 billion New Valence deal earlier in the month (BioCentury This Week, June 23).

Watch the antitrust clock on Paramount-WBD. Bloomberg Daybreak: US Edition (June 19) had the cleanest timeline: DOJ cleared the $110 billion Paramount-Skydance acquisition of Warner Bros. Discovery on June 16, but UK approval is due July 7 and the EU by August 7, with likely divestitures of children's channels. A September 30 ticking fee and roughly ten state AG investigations remain live, this deal is approved, not closed.

Exchanges and prediction markets are now openly at war. The week's most consequential structural fight: CME is suing the CFTC. On Fast Money (June 18), outgoing CME CEO Terry Duffy confirmed the litigation, arguing perpetual futures are not futures at all but swaps under Dodd-Frank, "when there's two parties exchanging payments to each other, that's deemed a swap," which would force prediction markets to register as swap dealers and post five-day margin. Duffy dismissed the threat to his book ("80% to 90% of my business is institutional driven... 133 million open positions with $300 billion of money protecting those positions") and insisted his exit, President Lynn Fitzpatrick succeeds him next March, was an eight-month board process, not a reaction to perps. The market disagreed: Nasdaq fell ~7%, ICE ~5%, CBOE ~4%.

On the other side, Kalshi's John Wang told Unchained (June 19) the offshore perps market is $90 trillion and called perps "the most pure trading instrument." Kalshi has done $5.5 billion in volume since launch, offering CFTC-regulated leverage (6x Bitcoin, 4.4x ETH); institutional volume is up 800% and the firm raised $1 billion at a $22 billion valuation, while ICE, NYSE's parent, has taken a stake in rival Polymarket (Tech Brew Ride Home, June 18). The incumbents-versus-insurgents structure of US derivatives is being redrawn in real time.

Macro overlay, the Warsh Fed changes the rules. Kevin Warsh's first FOMC was a regime change. The Fed held at 3.5 to 3.75% but cut the statement to ~131 words (from ~175 in April) and, per Bloomberg Surveillance (June 17), launched five task forces, communications, the balance sheet, data sources, productivity and jobs, and the inflation framework, to report by year-end. Warsh refused to submit his own dot. His philosophy, in his words: "financial markets perform best when they react to incoming data... less efficiently when they ask... how will the Federal Reserve react." The committee leaned hawkish, nine of 18 now pencil in 2026 hikes, the two-year jumped ~13bp to 4.18%, and Notes on the Week Ahead (June 22) put 100% odds on a hike by October. The read-through for deal-makers: a higher-for-longer funding backdrop just as the issuance wall arrives.

Also on the tape. Biotech is having its own boom: Cardigan's $400 million debut was the 13th biotech IPO of the year, near $5 billion of deal value and a post-pandemic high, with Nasdaq expecting as many as 25 for the year (Fast Money, June 18). The counterpoint: private credit looks "constipated," with US direct lending down 40%, PE-backed issuance down 37%, and LBO lending down 34%, as BlackRock and Blackstone vehicles cap redemptions (Eurodollar University, June 18).

The bottom line. The public-market machine is roaring back at the top of the cap structure, even as the plumbing underneath, private credit, exchange regulation, Fed communication, is being rewired. The supply wave, equity and debt, against a newly hawkish, deliberately quiet Fed is the tension to underwrite into H2. Watch the SpaceX August unlock, the Paramount-WBD July/August antitrust deadlines, and the CME-CFTC docket.